XCUR-FXN / Exicure - LARVOL DELTA

First In-human Trial of XCUR-FXN Planned for 2022 (Friedreich's Ataxia News) - "Exicure recently discussed preclinical research data and the next steps in developing XCUR-FXN...for Friedreich’s ataxia (FA), in a live webcast. After initiating investigational new drug (IND)-enabling studies of XCUR-FXN in late 2020 — intended to support regulatory clearance of clinical trials — the company plans to file an IND application to the U.S. Food and Drug Administration (FDA) by the end of the year, with the first-in-human trial planned for 2022."

IND • New trial • CNS Disorders • Friedreich ataxia

Exicure Announces Agenda for Upcoming Neuroscience Pipeline Update at Virtual R&D Day (Businesswire) - "Exicure, Inc....will host a virtual R&D Day on Thursday, January 7, 2021 from 09:00 am to 10:30 am ET to discuss Exicure’s neuroscience pipeline, including its lead program for Friedreich’s Ataxia (FA). Exicure will discuss its progress with XCUR-FXN, which advanced into IND-enabling studies in Q4 2020, and provide its perspective on the path for the product candidate to clinical validation for the treatment of Friedreich’s Ataxia...and highlight the advancement of two preclinical programs: one targeting SCN9A for neuropathic pain and the other targeting CLN3 Batten Disease."

Preclinical • CNS Disorders • Friedreich ataxia • Neuralgia • Pain • Peripheral Neuropathic Pain

Exicure Provides Neuroscience Pipeline Update at Virtual R&D Day (Businesswire) - "Exicure, Inc....announced that it will host a virtual R&D Day on Thursday, January 7th, 2021 from 09:00 am to 10:30 am ET to discuss Exicure’s neuroscience pipeline, including its lead program for Friedreich’s Ataxia which has progressed into IND-enabling studies. Exicure’s Scientific Advisory Board member Dr. Susan Perlman and the CEO of the Friedreich’s Ataxia Research Alliance (FARA) Jennifer Farmer, will join Exicure’s leadership team in discussing the company’s progress in Friedreich’s Ataxia and its expanding neuroscience pipeline."

Review • Friedreich ataxia

Exicure, Inc. Reports Second Quarter 2020 Financial Results and Corporate Progress (Businesswire) - "XCUR-FXN, Exicure’s Friedreich’s ataxia therapeutic candidate: We remain on track to initiate IND-enabling studies for Friedreich’s ataxia in the fourth quarter of this year."

New trial • Friedreich ataxia

Exicure, Inc. reports first quarter 2020 financial results and corporate progress (Businesswire) - "Research and development expenses were $6.1 million for the quarter ended March 31, 2020, compared to $3.4 million for the quarter ended March 31, 2019....The increase in staffing and associated increases in platform and discovery related costs reflects increased preclinical R&D activities associated with our collaboration with Allergan plc, increased costs related to XCUR-FXN, our Friedreich’s ataxia program...Exicure believes its SNA technology has the potential to address this genetic challenge....Exicure plans to design and develop XCUR-FXN with guidance from, and in collaboration with, the Friedreich’s Ataxia Research Alliance (FARA)."

Clinical • Licensing / partnership • Friedreich ataxia • Genetic Disorders

Exicure Provides business update amid Covid-19 pandemic (Businesswire) - "Exicure’s pre-clinical development program in Friedreich’s ataxia is being conducted in the Company’s R&D labs. Preclinical research is ongoing. The Company affirms its guidance that IND-enabling studies for XCUR-FXN are expected in late 2020."

IND • Preclinical